Skip to main content
main-content

19.01.2017 | SCLC | Onlineartikel

Immunotherapy: novel anti-PD-L1 antibodies & various combination regimens

Figure 1: Response rates with first-line atezolizumab in the BIRCH trial, according to PD-L1 expression status

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weiterführende Themen